Dalpiciclib Isethionate Tablets

This product, combined with fulvestrant, is indicated for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer who have progressed after previous endocrine therapy. [1]
This product, combined with an aromatase inhibitor as initial treatment, is indicated for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. [9]